[Sleep disturbances in Alzheimer's disease and other dementias]
- PMID: 20215095
- DOI: 10.1684/pnv.2010.0203
[Sleep disturbances in Alzheimer's disease and other dementias]
Abstract
Sleep in dementias has been mainly studied in Alzheimer disease (AD). Sleep disturbances are found in 25 to 35% of subjects with AD. Subjective and objective disturbances are described. Long nocturnal awakenings disrupt sleep; total sleep time and sleep efficiency are reduced. Slow wave sleep is decreased and sometimes disappears. REM sleep percentage is also reduced and at a later stage of the disease, REM latency is increased. Sleep fragmentation can be associated with excessive daytime napping and sleepiness, and with other behavioral symptoms such as the sundowning syndrome and nocturnal agitation. Sleep abnormalities closely parallel the level of severity of dementia. The rest/activity ratio and the sleep-wake rhythms are more and more disturbed; the phase delay of the temperature rhythm is associated with the severity of the sundowning syndrome. Sleep disturbances and behavioral symptoms are the main reasons to institutionalize the patient. Sleep disturbances are related to multiple factors. Pathophysiological changes resulting of the disease itself, such as damage to the cholinergic pathways and to the circadian pacemaker in the suprachiasmatic nucleus, contribute to sleep changes in AD. Associated medical and psychiatric illness and their different treatments as well as environmental factors also induced sleep disturbances. Sleep-disordered breathing is a highly prevalent condition in AD patients and restless leg syndrome may account for nocturnal agitation. In Parkinson and in Lewy body dementias, sleep disturbances are more severe than in DA and REM sleep behavior disorder can precede by several years these diseases. Sleep attacks and sleepiness are very frequent in Parkinson disease. Specific etiologies should drive specific treatment. Several non pharmacologic treatments are usually associated to treat sleep disturbances in AD: information, increased daytime physical, social activities to minimize daytime naps and exposure to bright light. Some studies found advantages to associate melatonin in the evening.
Similar articles
-
[A chronobiological approach in treatment of sleep disturbances in Alzheimer's dementia patients].Harefuah. 2006 Jun;145(6):437-40, 470. Harefuah. 2006. PMID: 16838900 Review. Hebrew.
-
Association of daytime napping and Parkinsonian signs in Alzheimer's disease.Sleep Med. 2006 Dec;7(8):614-8. doi: 10.1016/j.sleep.2006.02.006. Epub 2006 Oct 4. Sleep Med. 2006. PMID: 17023213
-
The use of melatonin in Alzheimer's disease.Neuro Endocrinol Lett. 2002 Apr;23 Suppl 1:20-3. Neuro Endocrinol Lett. 2002. PMID: 12019347 Review.
-
[Sleep disorders and dementia].Praxis (Bern 1994). 1997 Aug 27;86(35):1343-9. Praxis (Bern 1994). 1997. PMID: 9381026 Review. German.
-
Alzheimer's disease. Sleep and sleep/wake patterns.Clin Geriatr Med. 1989 May;5(2):289-99. Clin Geriatr Med. 1989. PMID: 2665912 Review.
Cited by
-
Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value.Int J Alzheimers Dis. 2010 Dec 8;2011:741974. doi: 10.4061/2011/741974. Int J Alzheimers Dis. 2010. PMID: 21197086 Free PMC article.
-
Sleep-Wake Cycle Dysfunction in the TgCRND8 Mouse Model of Alzheimer's Disease: From Early to Advanced Pathological Stages.PLoS One. 2015 Jun 15;10(6):e0130177. doi: 10.1371/journal.pone.0130177. eCollection 2015. PLoS One. 2015. PMID: 26076358 Free PMC article.
-
Relation between caffeine and behavioral symptoms in elderly patients with dementia: an observational study.J Nutr Health Aging. 2014 Apr;18(4):407-10. doi: 10.1007/s12603-013-0417-9. J Nutr Health Aging. 2014. PMID: 24676322
-
REM sleep atonia loss distinguishes synucleinopathy in older adults with cognitive impairment.Neurology. 2020 Jan 7;94(1):e15-e29. doi: 10.1212/WNL.0000000000008694. Epub 2019 Dec 12. Neurology. 2020. PMID: 31831602 Free PMC article.
-
A sleep continuity scale in Alzheimer's disease: validation and relationship with cognitive and functional deterioration.Neurol Sci. 2013 May;34(5):701-5. doi: 10.1007/s10072-012-1118-6. Epub 2012 May 24. Neurol Sci. 2013. PMID: 22622870
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical